Navigation Links
Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show
Date:8/13/2009

WORCESTER, Mass., Aug. 13 /PRNewswire-FirstCall/ -- Advanced Cell Technology, Inc., (OTC: ACTC) announced today that Dr. Robert Lanza, its Chief Scientific Officer, is featured on Deepak Chopra's Wellness Radio airing Saturday on Sirius/XM Stars, Channels 102 and 55 [Live Saturday 12 pm - 1 pm ET; Replays 1 pm - 4 am (Sunday) ET, and throughout the week]. The show focuses on Dr. Lanza's research at ACTC and his new book "Biocentrism." SIRIUS XM Stars Channel is the flagship satellite talk station featuring unique and diverse programs, including Deepak Chopra and broadcasting legend Barbara Walters, among others. It has a listenership of approximately 9 million people.

Chopra is a prolific author of over fifty-five books on topics ranging from health to consciousness and quantum mechanics, and was heralded by Time Magazine as one of the top heroes and icons of the century. On his show, Lanza discusses the cutting edge of regenerative medicine, including ACTC's efforts to use stem cells to treat blindness, vascular damage, and heart disease. ACTC hopes to file at least one application with the FDA this year to begin human clinical trials using retinal pigment epithelium (RPE) cells to treat macular degeneration and other retinal degenerative diseases.

Lanza and Chopra also discuss "Biocentrism," and how life and consciousness are the keys to understanding the true nature of the universe. "We think life is an accident of physics," explains Lanza. "But a long list of experiments suggests just the opposite. Amazingly, if you add life to the equation, you can explain some of the biggest puzzles of science. "

Deepak Chopra stated, "Having interviewed some of the most brilliant minds in the scientific world, I found Dr. Robert Lanza's insights into the nature of consciousness original and exciting. His theory of biocentrism is consistent with the most ancient wisdom traditions of the world which says that consciousness conceives, governs, and becomes a physical world. It is the ground of our Being in which both subjective and objective reality come into existence. I hope to have Dr. Lanza continue this conversation on Sirius XM satellite radio in the future."

"We believe that Dr. Lanza has contributed significantly to the understanding of the key role stem cells play in the field of regenerative medicine," said William M. Caldwell IV, Chairman and CEO of ACTC. "Through his scientific leadership the field is on the verge of therapeutically validating a new platform for regenerative medicine."

Click this link to listen to the Sirius/XM radio broadcast: http://www.sirius.com/siriusxmstars

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.


'/>"/>
SOURCE Advanced Cell Technology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
2. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
3. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
6. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
7. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
8. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
9. Hiemstra Appoints Robert C. Glines as Director of Business Development
10. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
11. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):